Stevanato Group S.p.A. (STVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Stevanato Group S.p.A. (STVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha • Sep 15, 2026

Baron Global Durable Advantage ETF Q2 2026 Portfolio Activity

During the second quarter, we initiated three new positions: a leading software and semiconductor company, Broadcom, Samsung Electronics, and INNIO. We took advantage of inflows and market volatility to add to 36 existing positions. We also exited three investments – Indutrade, HDFC Bank, and Wix – reallocating to names in which we saw a more attractive risk-reward profile.

Seeking Alpha • Sep 11, 2026

Stevanato Group to Participate in Two Upcoming Investor Conferences

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in two upcoming investor conferences: Tuesday, September 15, at 1:50 p.m. (ET) – Morgan Stanley Annual Global Healthcare Conference, New York, NY Tuesday, September 22, at 8:25 – 9:05 a.m. (GMT) – BofA Global Healthcare Confere.

Business Wire • Sep 8, 2026

Stevanato Group: Alina Validates The Container-To-Device Flywheel

Stevanato Group is transforming from a pharmaceutical glass supplier into an integrated drug containment and delivery platform, validated by commercial adoption of its Alina injector. High-value solutions now drive 45% of revenue, growing 16% year-over-year, with recent capacity investments in Fishers and Latina expected to boost operating leverage and margin expansion. STVN is shifting its portfolio toward premium, integrated offerings, divesting low-margin assets like Balda and focusing on durable, higher-margin customer relationships.

Seeking Alpha • Aug 29, 2026

Stevanato Group Q2 Earnings Call Highlights

Stevanato Group NYSE: STVN reported second-quarter 2026 revenue growth of 8% as demand for higher-value drug containment and delivery products helped lift profitability, while the company updated its full-year outlook to reflect the divestiture of its California-based Balda C. Brewer subsidiary.

MarketBeat • Aug 9, 2026

Is Stevanato (STVN) a Solid Growth Stock? 3 Reasons to Think "Yes"

Stevanato (STVN) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Zacks Investment Research • Aug 5, 2026

Stevanato Group S.p.A. (STVN) Q2 2026 Earnings Call Transcript

Stevanato Group S.p.A. (STVN) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 4, 2026

Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter of 2026. Second Quarter of 2026 Highlights (comparisons to prior-year period) Revenue increased 8% to €302.0 million, with high-value solutions representing 45% of total revenue. Gross profit margin increase.

Business Wire • Aug 4, 2026

Stevanato Group (STVN) Q2 Earnings Top Estimates

Stevanato Group (STVN) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.12 per share a year ago.

Zacks Investment Research • Aug 4, 2026

Liraglutide Combination Products Incorporating Stevanato Group's Alina® Pen Injector Received Marketing Authorizations in Multiple European Countries

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions for the pharmaceutical, biotechnology and life sciences industries, today announced that liraglutide-based combination products incorporating Stevanato Group's proprietary Alina® pen injector platform have received marketing authorizations in Europe. The authorizations relate to finished combination products held by the respective Mark.

Business Wire • Jul 30, 2026